Lisa E Vaughan
Overview
Explore the profile of Lisa E Vaughan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
786
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Chewcharat A, Thongprayoon C, Vaughan L, Mehta R, Schulte P, OConnor H, et al.
Mayo Clin Proc
. 2022 Aug;
97(8):1437-1448.
PMID: 35933132
Objective: To compare dietary factors between incident symptomatic stone formers and controls, and among the incident stone formers, to determine whether dietary factors were predictive of symptomatic recurrence. Patients And...
12.
Farooqui N, Sy-Go J, Miao J, Mehta R, Vaughan L, Bennani N, et al.
Mayo Clin Proc
. 2022 Jul;
97(7):1294-1304.
PMID: 35787856
Objective: To evaluate the association of baseline and postinfusion patient characteristics with acute kidney injury (AKI) in the month after chimeric antigen receptor T-cell (CAR-T) therapy. Methods: We retrospectively reviewed...
13.
Singh P, Vaughan L, Schulte P, Sas D, Milliner D, Lieske J
Am J Kidney Dis
. 2022 Mar;
80(3):373-382.
PMID: 35306035
Rationale & Objective: Primary hyperoxaluria type 1 (PH1) is an autosomal recessive disorder of glyoxylate metabolism that results in early-onset kidney stone disease, nephrocalcinosis, and kidney failure. There is an...
14.
Creo A, Sriram S, Vaughan L, Weaver A, Lteif A, Kumar S
Pediatr Diabetes
. 2021 Sep;
22(8):1143-1149.
PMID: 34561948
Background: Adolescents and emerging adults with chronic health conditions such as type 1 diabetes mellitus (T1D) are more likely to engage in high-risk behaviors. Previous studies regarding substance use in...
15.
Azer S, Vaughan L, Tebben P, Sas D
J Endocr Soc
. 2021 Aug;
5(9):bvab119.
PMID: 34337279
Context: CYP24A1 encodes 24-hydroxylase, which converts 25(OH)D3 and 1,25(OH)D to inactive metabolites. Loss-of-function variants in CYP24A1 are associated with 24-hydroxylase deficiency (24HD), characterized by hypercalcemia, nephrolithiasis, and nephrocalcinosis. We retrospectively...
16.
Laughlin-Tommaso S, Gorny K, Hesley G, Vaughan L, Woodrum D, Lemens M, et al.
J Womens Health (Larchmt)
. 2021 Jul;
31(4):546-554.
PMID: 34242085
Women with uterine fibroids often seek uterine-preserving treatments, rather than hysterectomy. Imaging-defined endpoints following nonsurgical treatments for fibroids are limited. Fibroid Interventions: Reducing Symptoms Today and Tomorrow (FIRSTT), a randomized...
17.
Thongprayoon C, Vaughan L, Chewcharat A, Kattah A, Enders F, Kumar R, et al.
Am J Kidney Dis
. 2021 Apr;
78(3):409-417.
PMID: 33867205
Rationale & Objective: There are several well-known anatomical and physiological changes during pregnancy that could contribute to kidney stone formation, but evidence that they increase the risk of kidney stones...
18.
Shukoor S, Vaughan L, Edwards M, Lavu S, Kline T, Senum S, et al.
Kidney Int Rep
. 2021 Mar;
6(3):755-767.
PMID: 33732990
Introduction: Cystic expansion damaging the parenchyma is thought to lead to end-stage kidney disease (ESKD) in autosomal dominant polycystic kidney disease (ADPKD). Here we characterized genotypic and phenotypic attributes of...
19.
Drosou M, Vaughan L, Muchtar E, Buadi F, Dingli D, Dispenzieri A, et al.
Am J Hematol
. 2021 Jan;
96(4):446-454.
PMID: 33428787
Three sets of criteria (International Society of Amyloidosis [ISA], Palladini and Kastritis) were independently developed for staging, progression and response criteria to predict renal survival in patients with AL amyloidosis....
20.
Hogan M, Chamberlin J, Vaughan L, Waits A, Banks C, Leistikow K, et al.
Clin J Am Soc Nephrol
. 2020 Aug;
15(9):1267-1278.
PMID: 32843370
Background And Objectives: We assessed safety and efficacy of another somatostatin receptor analog, pasireotide long-acting release, in severe polycystic liver disease and autosomal dominant polycystic kidney disease. Pasireotide long-acting release,...